Home › Compare › KNBWF vs ABBV
KNBWF yields 2.80% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, KNBWF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KNBWF + ABBV for your $10,000?
Kirin Holdings Company, Limited produces and sells alcoholic beverages, soft drinks, pharmaceuticals, and other related products in Japan and internationally. It operates through four segments: Japan Beer and Spirits Businesses, Japan Non-Alcoholic Beverages Business, Oceania Integrated Beverages Business, and Pharmaceuticals Business. The company's products include beer, happo-shu, wine, whiskey, spirits, soft drinks, dairy products, fruit juices, and other products. It also produces and sells pharmaceutical products, biochemical products, and other products. In addition, the company engages in the factories and theme park businesses; management and operation of a chain of Kirin City beer pubs; and manufacture and sale of amino acids and nucleic acids for pharmaceutical and industrial use bulk pharmaceuticals, as well as margarine, jams, and honey. Further, it is involved in the manufacture and sale of Coca-Cola products and other soft drinks, and sake and other food products; as well as manufacture and supply of Four Roses bourbon; and acts as an insurance agent. The company was formerly known as Kirin Brewery Company, Limited and changed its name to Kirin Holdings Company, Limited in July 2007. Kirin Holdings Company, Limited was founded in 1885 and is headquartered in Tokyo, Japan.
Full KNBWF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.